Awareness and clinical use of Lp(a) testing among LATAM physicians is low, indicating a missed opportunity for improving cardiovascular risk assessment.
Awareness and clinical use of Lp(a) testing among Latin American physicians is limited, highlighting a need for improved accessibility and clearer guidelines.
Absolute Event Rate: 0% vs 0%
Awareness and clinical use of Lp(a) testing among LATAM physicians remain limited and focused on high-risk scenarios. Improving test accessibility, providing clearer clinical guidelines, and reinforcing the evidence for Lp(a) as a therapeutic target may enhance its adoption and integration into cardiovascular risk assessment across the region.
Cruz‐Bautista et al. (Mon,) reported a other. Awareness and clinical use of Lp(a) testing among LATAM physicians is low, indicating a missed opportunity for improving cardiovascular risk assessment.